Symbols / SCNI Stock $0.35 -13.08% Scinai Immunotherapeutics Ltd.

Healthcare • Biotechnology • Israel • NCM
SCNI (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Amir Reichman M.B.A., M.Sc.
Exch · Country NCM · Israel
Market Cap 1.40M
Enterprise Value 7.46M
Income -8.31M
Sales 1.31M
FCF (ttm) -3.33M
Book/sh 0.71
Cash/sh 0.48
Employees 45
Insider 10d —
IPO May 11, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E inf
Forward P/E —
PEG —
P/S 1.07
P/B 0.50
P/C —
EV/EBITDA -1.22
EV/Sales 5.69
Quick Ratio 1.15
Current Ratio 1.30
Debt/Eq 27.98
LT Debt/Eq —
EPS (ttm) 0.00
EPS next Y —
EPS Growth —
Revenue Growth 30.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2024-05-15
Earnings (prior) 2024-05-15
ROA -37.60%
ROE -91.89%
ROIC —
Gross Margin -202.29%
Oper. Margin -7.02%
Profit Margin 0.00%
Shs Outstand 3.96M
Shs Float 3.10M
Insider Own 10.15%
Instit Own 3.19%
Short Float 2.48%
Short Ratio 0.41
Short Interest 97.74K
52W High 3.48
vs 52W High -89.82%
52W Low 0.34
vs 52W Low 3.08%
Beta 2.05
Impl. Vol. —
Rel Volume 0.07
Avg Volume 3.43M
Volume 225.08K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.41
Price $0.35
Change -13.08%
About

Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.35
Latest analyst target
3. DCF / Fair value
$-15.13
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.35
Low
—
High
—
Mean
—
News
RSS: Latest SCNI news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1.31
+99.24%
0.66
0.00
0.00
Operating Revenue
1.31
+99.24%
0.66
0.00
0.00
Cost Of Revenue
3.96
+220.11%
1.24
0.00
0.00
Reconciled Cost Of Revenue
3.96
+220.11%
1.24
0.00
0.00
Gross Profit
-2.65
-357.24%
-0.58
0.00
0.00
Operating Expense
4.89
-39.31%
8.06
-16.98%
9.71
-12.25%
11.06
Research And Development
2.37
-57.18%
5.53
+6.18%
5.21
-9.63%
5.76
Selling General And Administration
2.52
-0.20%
2.53
-43.93%
4.50
-14.94%
5.30
General And Administrative Expense
—
—
—
—
Salaries And Wages
—
—
—
—
Other Gand A
—
—
—
—
Other Operating Expenses
—
—
-0.01
—
Total Expenses
8.85
-4.77%
9.30
-4.22%
9.71
-12.25%
11.06
Operating Income
-7.54
+12.69%
-8.64
+11.00%
-9.71
+12.25%
-11.06
Total Operating Income As Reported
-7.54
+12.69%
-8.64
+11.00%
-9.71
+12.25%
-11.06
EBITDA
-6.53
-182.97%
7.87
+460.05%
-2.19
+58.25%
-5.23
Normalized EBITDA
-6.11
+11.42%
-6.90
-30.76%
-5.28
+29.36%
-7.47
Reconciled Depreciation
1.42
-13.83%
1.65
+220.82%
0.51
-8.54%
0.56
EBIT
-7.95
-227.82%
6.22
+330.38%
-2.70
+53.43%
-5.80
Total Unusual Items
-0.42
-102.82%
14.77
+377.71%
3.09
+38.30%
2.23
Total Unusual Items Excluding Goodwill
-0.42
-102.82%
14.77
+377.71%
3.09
+38.30%
2.23
Special Income Charges
0.00
-100.00%
14.76
0.00
0.00
Other Special Charges
—
-14.76
—
—
Net Income
-8.31
-273.21%
4.80
+173.78%
-6.50
-12.15%
-5.80
Pretax Income
-8.31
-273.21%
4.80
+173.78%
-6.50
-12.15%
-5.80
Net Non Operating Interest Income Expense
-0.35
+73.80%
-1.33
-1258.26%
0.12
-96.20%
3.03
Interest Expense Non Operating
0.36
-74.75%
1.42
-62.59%
3.80
0.00
Net Interest Income
-0.35
+73.80%
-1.33
-1258.26%
0.12
-96.20%
3.03
Interest Expense
0.36
-74.75%
1.42
-62.59%
3.80
0.00
Interest Income Non Operating
0.02
-80.00%
0.10
-97.45%
3.92
+28.61%
3.05
Interest Income
0.02
-80.00%
0.10
-97.45%
3.92
+28.61%
3.05
Other Income Expense
-0.42
-102.82%
14.77
+377.71%
3.09
+38.30%
2.23
Gain On Sale Of Security
-0.42
-6042.86%
0.01
-99.77%
3.09
+38.30%
2.23
Tax Rate For Calcs
0.00
-100.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
3.40
0.00
0.00
Net Income Including Noncontrolling Interests
-8.31
-273.21%
4.80
+173.78%
-6.50
-12.15%
-5.80
Net Income From Continuing Operation Net Minority Interest
-8.31
-273.21%
4.80
+173.78%
-6.50
-12.15%
-5.80
Net Income From Continuing And Discontinued Operation
-8.31
-273.21%
4.80
+173.78%
-6.50
-12.15%
-5.80
Net Income Continuous Operations
-8.31
-273.21%
4.80
+173.78%
-6.50
-12.15%
-5.80
Normalized Income
-7.89
-20.04%
-6.57
+31.46%
-9.59
-19.42%
-8.03
Net Income Common Stockholders
0.00
0.00
+100.00%
-6.50
-12.15%
-5.80
Diluted EPS
—
0.00
+100.00%
-16.00
+60.00%
-40.00
Basic EPS
—
0.00
+100.00%
-16.00
+60.00%
-40.00
Basic Average Shares
—
0.81
+106.41%
0.39
+107.22%
0.19
Diluted Average Shares
—
0.81
+106.41%
0.39
+107.22%
0.19
Diluted NI Availto Com Stockholders
0.00
0.00
+100.00%
-6.50
-12.15%
-5.80
Depreciation Amortization Depletion Income Statement
—
—
—
—
Depreciation And Amortization In Income Statement
—
—
—
—
Depreciation Income Statement
—
—
—
—
Preferred Stock Dividends
-8.31
-273.21%
4.80
—
—
Rent And Landing Fees
—
—
—
—
Rent Expense Supplemental
—
—
—
—
Total Other Finance Cost
0.01
+0.00%
0.01
+25.00%
0.01
-61.90%
0.02
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
11.63
-13.55%
13.45
-23.03%
17.47
-35.45%
27.07
Current Assets
2.05
-14.09%
2.39
-56.10%
5.45
-62.09%
14.37
Cash Cash Equivalents And Short Term Investments
1.66
-15.43%
1.96
-59.67%
4.87
-65.40%
14.07
Cash And Cash Equivalents
1.66
-15.43%
1.96
-59.67%
4.87
-65.40%
14.07
Cash Financial
—
—
—
—
Receivables
0.17
-22.58%
0.22
-40.71%
0.37
+232.73%
0.11
Accounts Receivable
0.07
-12.05%
0.08
0.00
—
Other Receivables
0.10
-29.10%
0.13
-63.39%
0.37
+232.73%
0.11
Prepaid Assets
0.07
-5.06%
0.08
+11.27%
0.07
+57.78%
0.04
Restricted Cash
0.15
+14.50%
0.13
-6.43%
0.14
+0.00%
0.14
Total Non Current Assets
9.57
-13.43%
11.06
-8.05%
12.03
-5.29%
12.70
Net PPE
9.57
-13.43%
11.06
-8.05%
12.03
-5.29%
12.70
Gross PPE
15.45
-0.42%
15.51
+4.58%
14.83
-1.89%
15.12
Accumulated Depreciation
-5.88
-31.87%
-4.46
-58.69%
-2.81
-15.99%
-2.42
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
—
—
—
—
Machinery Furniture Equipment
7.78
+0.06%
7.77
+2321.18%
0.32
-3.31%
0.33
Construction In Progress
—
0.00
-100.00%
7.45
-4.90%
7.83
Other Properties
3.95
-1.74%
4.02
+20.23%
3.34
+9.93%
3.04
Leases
3.72
+0.00%
3.72
+0.00%
3.72
-4.90%
3.92
Other Non Current Assets
—
—
—
—
Total Liabilities Net Minority Interest
3.52
+1.50%
3.47
-84.25%
22.04
-23.54%
28.83
Current Liabilities
1.58
-12.24%
1.81
+1.46%
1.78
-23.87%
2.34
Payables And Accrued Expenses
1.17
+0.78%
1.16
-16.40%
1.38
-29.24%
1.96
Payables
0.41
+8.24%
0.38
-29.72%
0.54
-25.28%
0.72
Accounts Payable
0.41
+8.24%
0.38
-29.72%
0.54
-25.28%
0.72
Current Accrued Expenses
0.76
-2.82%
0.78
-8.01%
0.85
-31.53%
1.24
Employee Benefits
—
—
—
—
Pensionand Other Post Retirement Benefit Plans Current
—
—
—
0.48
Current Debt And Capital Lease Obligation
0.33
-22.41%
0.42
+7.07%
0.40
+3.66%
0.38
Current Capital Lease Obligation
0.33
-22.41%
0.42
+7.07%
0.40
+3.66%
0.38
Current Deferred Liabilities
0.09
-60.00%
0.23
0.00
—
Current Deferred Revenue
0.09
-60.00%
0.23
0.00
—
Total Non Current Liabilities Net Minority Interest
1.94
+16.40%
1.67
-91.78%
20.26
-23.51%
26.49
Long Term Debt And Capital Lease Obligation
1.94
+16.61%
1.66
-91.76%
20.16
-4.70%
21.16
Long Term Debt
0.29
+13.08%
0.26
-98.66%
19.37
-3.56%
20.08
Long Term Capital Lease Obligation
1.64
+17.26%
1.40
+75.91%
0.80
-26.07%
1.08
Non Current Pension And Other Postretirement Benefit Plans
—
—
—
—
Tradeand Other Payables Non Current
—
—
—
—
Stockholders Equity
8.10
-18.78%
9.98
+318.36%
-4.57
-159.60%
-1.76
Common Stock Equity
2.48
-43.08%
4.35
+195.21%
-4.57
-159.60%
-1.76
Capital Stock
5.63
+0.00%
5.63
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Preferred Stock
5.63
+0.00%
5.63
0.00
—
Share Issued
13,872.90
+306.59%
3,411.98
+83.72%
1,857.17
+87.73%
989.29
Ordinary Shares Number
13,872.90
+306.59%
3,411.98
+83.72%
1,857.17
+87.73%
989.29
Additional Paid In Capital
130.06
+5.20%
123.63
+3.45%
119.51
+2.95%
116.08
Retained Earnings
-125.85
-7.07%
-117.54
+3.92%
-122.33
-5.61%
-115.83
Gains Losses Not Affecting Retained Earnings
-1.74
+0.00%
-1.74
+0.00%
-1.74
+13.30%
-2.01
Other Equity Adjustments
-1.74
+0.00%
-1.74
+0.00%
-1.74
+13.30%
-2.01
Total Equity Gross Minority Interest
8.10
-18.78%
9.98
+318.36%
-4.57
-159.60%
-1.76
Total Capitalization
8.40
-17.97%
10.24
-30.83%
14.80
-19.23%
18.32
Working Capital
0.47
-19.83%
0.58
-84.05%
3.67
-69.52%
12.03
Invested Capital
2.77
-39.91%
4.61
-68.85%
14.80
-19.23%
18.32
Total Debt
2.27
+8.68%
2.09
-89.85%
20.56
-4.55%
21.54
Net Debt
—
—
14.50
+141.35%
6.01
Capital Lease Obligations
1.97
+8.05%
1.83
+53.06%
1.19
-18.29%
1.46
Net Tangible Assets
8.10
-18.78%
9.98
+318.36%
-4.57
-159.60%
-1.76
Tangible Book Value
2.48
-43.08%
4.35
+195.21%
-4.57
-159.60%
-1.76
Derivative Product Liabilities
0.00
-100.00%
0.00
-96.88%
0.10
-98.20%
5.33
Preferred Stock Equity
5.63
+0.00%
5.63
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-6.03
+4.80%
-6.33
+32.48%
-9.38
-29.14%
-7.26
Cash Flow From Continuing Operating Activities
-6.03
+4.80%
-6.33
+32.48%
-9.38
-29.14%
-7.26
Net Income From Continuing Operations
-8.31
-273.21%
4.80
+173.78%
-6.50
-12.15%
-5.80
Depreciation Amortization Depletion
1.42
-13.83%
1.65
+220.82%
0.51
-8.54%
0.56
Depreciation
1.42
-13.83%
1.65
+220.82%
0.51
-8.54%
0.56
Depreciation And Amortization
1.42
-13.83%
1.65
+220.82%
0.51
-8.54%
0.56
Other Non Cash Items
0.39
+102.91%
-13.48
-3461.85%
0.40
+110.27%
-3.90
Pension And Employee Benefit Expense
—
—
—
—
Stock Based Compensation
0.30
-55.57%
0.68
-40.12%
1.14
-28.90%
1.60
Operating Gains Losses
-0.00
+96.77%
-0.09
+97.75%
-4.14
—
Gain Loss On Investment Securities
-0.00
+96.77%
-0.09
+97.75%
-4.14
—
Change In Working Capital
0.16
+45.54%
0.11
+114.07%
-0.80
-393.73%
0.27
Change In Receivables
0.05
-62.41%
0.14
+148.62%
-0.29
-307.14%
0.14
Changes In Account Receivables
0.01
+112.05%
-0.08
0.00
—
Change In Payables And Accrued Expense
-0.13
-12700.00%
0.00
+100.20%
-0.49
-466.42%
0.13
Change In Payable
-0.13
-12700.00%
0.00
+100.20%
-0.49
-466.42%
0.13
Change In Account Payable
0.03
+119.87%
-0.16
-4.00%
-0.15
+14.29%
-0.17
Change In Other Current Assets
0.09
-68.66%
0.28
+560.47%
0.04
-71.90%
0.15
Change In Other Current Liabilities
0.15
+146.82%
-0.31
-441.38%
-0.06
+62.82%
-0.16
Investing Cash Flow
-0.02
-100.00%
-0.01
+98.12%
-0.64
+23.80%
-0.84
Cash Flow From Continuing Investing Activities
-0.02
-100.00%
-0.01
+98.12%
-0.64
+23.80%
-0.84
Net PPE Purchase And Sale
-0.02
-100.00%
-0.01
+98.12%
-0.64
+23.80%
-0.84
Purchase Of PPE
-0.02
-100.00%
-0.01
+98.12%
-0.64
+23.80%
-0.84
Sale Of PPE
—
—
—
—
Capital Expenditure
-0.02
-100.00%
-0.01
+98.12%
-0.64
+23.80%
-0.84
Net Other Investing Changes
—
—
—
—
Financing Cash Flow
5.77
+67.68%
3.44
+216.85%
1.09
-83.97%
6.78
Cash Flow From Continuing Financing Activities
5.77
+67.68%
3.44
+216.85%
1.09
-83.97%
6.78
Net Issuance Payments Of Debt
—
—
—
—
Issuance Of Debt
—
—
—
—
Repayment Of Debt
—
—
—
—
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
5.77
+188.50%
2.00
+1338.85%
0.14
-85.09%
0.93
Proceeds From Stock Option Exercised
—
1.44
+52.16%
0.95
-83.80%
5.84
Changes In Cash
-0.28
+90.19%
-2.91
+67.47%
-8.93
-574.19%
-1.32
Effect Of Exchange Rate Changes
0.00
+111.11%
-0.01
+96.69%
-0.27
+86.24%
-1.98
Beginning Cash Position
2.10
-58.18%
5.01
-64.76%
14.21
-18.85%
17.52
End Cash Position
1.81
-13.56%
2.10
-58.18%
5.01
-64.76%
14.21
Free Cash Flow
-6.05
+4.60%
-6.35
+36.65%
-10.02
-23.68%
-8.10
Interest Paid Supplemental Data
0.00
-100.00%
0.14
-82.83%
0.83
-9.06%
0.92
Common Stock Issuance
5.77
+188.50%
2.00
+1338.85%
0.14
-85.09%
0.93
Interest Paid CFO
—
—
—
—
Interest Received CFO
—
—
—
—
Issuance Of Capital Stock
5.77
+188.50%
2.00
+1338.85%
0.14
-85.09%
0.93
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category